brharris and that's just the point, that's the reason why in my opinion GC has started the uplisting too early. First thing first!
I had thought GC would have given the Market first more detailed information about the Lymprotest, more research about how well it'is excepted by the Medicare, commersialsation still this year as he stated nummerous times? The same for MSPrecise.
That translated into facts would have given the "Listing" a boost.
a postiv signal, which makes it easier for Institutionals to step in.
It makes AMBS more trustworthy.
Hopefully GC can give us more detailed information about these tests, soon after the uplisting.
If he comes out with the news that it is still an ungoing concern, I tell you he missed the boat. Don't forget that he already for months now wanted the Market to believe that LYmpro will be commersialized already this year! We're in september that means he minimal has to be in serious talks with a partner for some time and that he can give us more detailed information very soon!
Institutionals want to know where they put there money in. The partner they choose must be very trustworty. GC still has to prove that!
I suppose he knows damn well what he is doing. We're running out of money, investors are desperate needed.
Another R/S in this case is absolute no option. Should it happen
he will sign his own deadcentage. AMBS wouldn't be traded on the Nasdaq very long.
GC has to unveil his plans rather sooner than later! That's a fact.
The way I see it the only possibility there is that GC will surprice the Market, perhaps not today but soon after. I'm positiv about that. GC is a smart guy.
News 
Market Data 
Discover 
